epa glp 1 GLP-1 Support | Appetite support for cravings and fullness control GLP-1 Advanced Intra-Oral Spray, by

RSL3 inhibits the activity of GPX4, leading to a reduction in cellular antioxidant capacity and ROS accumulation, and ultimately to ferroptotic cell death (Yang et al., 2014)

When you're already on a GLP-1 agonist, appetite suppression is handled

It was approved in the UK in 2023 for weight management in adults with: BMI 30 kg/m (obesity), or BMI 27 kg/m (overweight) with at least one weight-related condition The medication works through several mechanisms: Reduces hunger signals by acting on the brains appetite control centre Slows stomach emptying , creating longer-lasting fullness after meals Reduces food cravings , particularly for ultra-processed foods Improves blood sugar control by enhancing insulin function Clinical trials show that people taking Wegovy lose an average of 15% of their body weight after 68 weeks, compared to 2.4% with placebo

L.HuangD